An interventional study of Clinical imaging is performed during the 24 and 60 month follow-up visits in Osteoporosis, sponsored by AgNovos Healthcare, LLC. Active, not recruiting at 1 site in Belgium. Open to female participants. Per ClinicalTrials.gov, last updated 2025-01-31.
Sponsored by AgNovos Healthcare, LLC · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Osteoporosis with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis · Belgium.
Among the 32 studies in Osteoporosis with a site in Belgium, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2020, is one of 9 with no phase, and was the 27th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →4 of the 32 studies in Osteoporosis with a site in Belgium are open now. Recruiting first, the newest first:
Imelda Hospital, Bonheiden · Sites in Belgium
Ages 55+
AgNovos Healthcare, LLC · Sites in Belgium
Women only
AgNovos Healthcare, LLC · Sites in Belgium, Austria, Canada and 8 more countries
Ages 65–91 · Women only
AgNovos Healthcare, LLC · Sites in Belgium
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 218 across the 27 interventional studies, 54 across the 5 observational. Of the 26 that completed or were terminated, 14 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 10 most frequent:
AgNovos Healthcare, LLC is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
AgNovos Healthcare, LLC has 7 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteoporosis with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07594639AgNovos Healthcare, LLCGRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP) | 2027-04-01 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Osteoporosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is designed as a multi-center study within Europe in up to 60 patients treated with the AGN1 LOEP Kit in CONFIRM. This will be a non-randomized and non-blinded study. The study will collect long-term follow-up data on the safety and clinical performance of AGN1 LOEP.
To qualify, subjects must have previously consented, enrolled, and been treated with the AGN1 LOEP kit in CONFIRM (AgNovos Study PST-EU-101.1).
Follow-up evaluations will be conducted at 24, 36, 48 and 60 months from the date the subject originally received the AGN1 LOEP treatment. Subjects will receive DXA and X-ray imaging at the 24- and 60-month follow-up visits. The 36- and 48-month follow-up evaluations will be conducted by phone. All timepoints will include general health and medical record review.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.
Other: Clinical imaging is performed during the 24 and 60 month follow-up visits
X-ray and DXA scan
Change in DXA score at 24 months
Change in DXA score of treated hip from baseline pre-AGN1 LOEP to 24 months post-treatment.
Time frame: 24 months
Change in DXA score at 60 months
Change in DXA score of treated hip from pre-AGN1 LOEP to 60 months post-treatment.
Time frame: 60 months
Hip fracture incidence
The incidence of hip fracture on the treated side during the follow-up period through 60 months post-AGN1 LOEP treatment.
Time frame: 60 months
Radiologic bone formation
Radiologic appearance of bone formation as assessed by X-ray at 24 and 60 months post-treatment.
Time frame: 60 months
Safety evaluation
The incidence of all serious adverse events during follow-up determined to be at least possibly related to the procedure and/or device through 60 months post-AGN1 LOEP treatment.
Time frame: 60 months
Plan to share: No
Started Aug 2020 (actual). Primary completion is estimated for Dec 2025, 64 months after the start.
Of 239 interventional studies with no phase under Osteoporosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 50. This study's planned 64 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AgNovos Healthcare, LLC